Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial BURY, MA – December 20, 2024 – Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745). The Corvia […]
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, MA – October 25, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF II randomized clinical trial confirming […]
Responder group patients with the shunt experience a 50% lower heart failure event rate and a 46% improvement in quality of life over control group TEWKSBURY, MA – August 19, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JACC-HF of two-year data from the […]
Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function TEWKSBURY, MA – May 7, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial […]
Second major trial for atrial shunt therapy demonstrates importance of patient selection TEWKSBURY, MA – April 12, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave’s RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the […]
First-ever phase III randomized controlled trial of atrial shunt therapy shows continued promise TEWKSBURY, MA – May 22, 2023 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt […]
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, MA – December 6, 2022 Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure […]
Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, MA – JUNE 9, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing from its existing investor syndicate. Funds will be utilized to support a […]
Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, MA – APRIL 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) […]
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, MA – FEBRUARY 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in […]
